🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

REMS Requirement Being Removed for Clozapine

FDA Approves MIUDELLA (Copper Intrauterine System) for the Prevention of Pregnancy

New ACC/AHA Acute Coronary Syndromes Guideline

FDA Recommends Class-Wide Labeling Changes for Testosterone Products

FDA Approves TNKase (Tenecteplase) for Acute Ischemic Stroke in Adults

FDA Approves ARBLI (Losartan) Oral Suspension

Hypertension and Raynaud’s Phenomenon Warnings Added to CGRP Antagonist Labels

FDA Approves BLUJEPA (Gepotidacin), a First-in-Class Oral Antibiotic, for the Treatment of Uncomplicated UTI

FDA Grants Marketing Authorization for the First Home Test for Chlamydia, Gonorrhea, and Trichomoniasis

“Are you afraid of the recent increase in new antibiotic approvals?” ESBLs:

2025 Global Strategy for Asthma Management and Prevention (GINA Report) Published

Pyrls is excited to announce the release of a new type of content item: Mechanism of Action Summaries! The foundation for making high-quality pharmacotherapy recommendations is an understanding of physiology and pharmacology. Each summary reviews a key physiological process

2025 CDC nPEP Recommendations Published

FDA Approves the First At-Home Self-Collection Device (TEAL WAND) for Cervical Cancer Screening

FDA Warns of Rare & Severe Itching After Stopping Long-Term Use of Cetirizine or Levocetirizine

FDA Approves NUCALA (Mepolizumab) for the Treatment of COPD in Adults

FDA Approves TRYPTYR (Ophthalmic Acoltremon) for the Treatment of Dry Eye Disease

FDA Approves WIDAPLIK (Telmisartan, Amlodipine, Indapamide) for the Treatment of Hypertension

FDA Approves ENFLONSIA (clesrovimab-cfor) for Prevention of RSV Lower Respiratory Tract Disease in Infants

FDA Approves MAVYRET (Glecaprevir/Pibrentasvir) for the Treatment of Acute HCV infection